49BA:F:F-BeiGene Ltd (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 170

Change

-1.00 (-0.58)%

Market Cap

USD 18.99B

Volume

15.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
CSJ:F CSL Limited

+2.46 (+1.44%)

USD 82.25B
CSJA:F CSL LTD SPON.ADR 2

+1.00 (+1.18%)

USD 80.95B
RGO:F Regeneron Pharmaceuticals Inc

-7.80 (-1.10%)

USD 74.41B
1AE:F Argen-X

+16.20 (+2.61%)

USD 36.18B
1AEA:F argenx SE

+10.00 (+1.64%)

USD 36.18B
UNC0:F UCB S.A. UNSP.ADR 1/2

+1.00 (+1.07%)

USD 35.06B
DUL:F Alnylam Pharmaceuticals Inc

+4.40 (+1.98%)

USD 29.18B
22UA:F BioNTech SE

-1.50 (-1.25%)

USD 26.21B
49B:F BeiGene Ltd.

N/A

USD 20.08B
0QF:F Moderna Inc

-4.63 (-9.88%)

USD 14.82B

ETFs Containing 49BA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.16% 33% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.16% 33% F 30% F
Trailing 12 Months  
Capital Gain 4.29% 63% D 51% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.29% 62% D 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -5.96% 49% F 27% F
Dividend Return -5.96% 49% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 29.46% 67% D+ 47% F
Risk Adjusted Return -20.22% 48% F 28% F
Market Capitalization 18.99B 98% N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.